FDA Halts Use of Some COVID Monoclonal Antibodies Due to Omicron FDA Halts Use of Some COVID Monoclonal Antibodies Due to Omicron

Bamlanivimab/etesevimab and casirivimab/imdevimab are highly unlikely to be active against the Omicron variant, which now makes up virtually all cases of COVID-19 in the United States, the FDA says.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Infectious Diseases News Source Type: news